Menu Search
Equities

Edwards Lifesciences Corp

EWL:DUS

Edwards Lifesciences Corp

Actions
  • Price (EUR)60.87
  • Today's Change0.20 / 0.33%
  • Shares traded81.00
  • 1 Year change-9.90%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 15:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Edwards Lifesciences Corp's net income fell -7.85% from 1.52bn to 1.40bn despite revenues that grew 11.56% from 5.38bn to 6.00bn. An increase in the cost of goods sold as a percentage of sales from 20.07% to 22.98% was a component in the falling net income despite rising revenues.
Gross margin77.58%
Net profit margin25.17%
Operating margin26.77%
Return on assets15.14%
Return on equity21.00%
Return on investment17.44%
More ▼

Cash flow in USDView more

In 2023, Edwards Lifesciences Corp increased its cash reserves by 48.59%, or 375.40m. The company earned 895.80m from its operations for a Cash Flow Margin of 14.92%. In addition the company generated 173.80m cash from investing, though they paid out 711.00m more in financing than they received.
Cash flow per share2.62
Price/Cash flow per share25.64
Book value per share12.35
Tangible book value per share9.74
More ▼

Balance sheet in USDView more

Edwards Lifesciences Corp has a Debt to Total Capital ratio of 7.37%, a lower figure than the previous year's 9.36%.
Current ratio3.71
Quick ratio2.87
Total debt/total equity0.0803
Total debt/total capital0.0737
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)14.85
EPS (TTM) vs
TTM 1 year ago		13.30
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.